Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.